The IL-17 and IL-23 inhibitor, ustekinumab, is also used in the treatment of psoriatic arthritis and has been shown to have a similar safety profile when compared to other monoclonal antibodies, such as secukinumab, with fewer severe adverse events [87]. This evidence concerns the gene IL17A and psoriatic arthritis.